Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SCN4A | P35499 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10434028 | 0.87 | NQO1 (0.48) | NQO1SCN5AALDH1A1KDM4EGRM5 | |
| SCHEMBL12180442 | 0.84 | ALDH1A1 (0.45) | NQO1SCN5AALDH1A1HTTKDM4E | |
| SCHEMBL23361704 | 0.84 | ALDH1A1 (0.49) | NQO1ALDH1A1HTTKDM4EHPGD | |
| SCHEMBL16372678 | 0.82 | MEN1 (0.42) | NQO1SCN5AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL2117233 | 0.82 | NQO1 (0.36) | NQO1ALDH1A1KDM4EGRM5HPGD | |
| SCHEMBL11062080 | 0.82 | SCN5A (0.43) | NQO1SCN5AALDH1A1KDM4EHPGD | |
| SCHEMBL25344472 | 0.82 | NQO1 (0.36) | NQO1ALDH1A1SMN1; SMN2KDM4EGRM5 | |
| SCHEMBL27514230 | 0.82 | ALDH1A1 (0.42) | NQO1SCN5AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL14430044 | 0.81 | ALDH1A1 (0.42) | SCN5AALDH1A1SMN1; SMN2HTTKDM4E | |
| SCHEMBL11215025 | 0.81 | ALDH1A1 (0.40) | NQO1SCN5AALDH1A1KDM4EGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021122437-A1 | FORMATION OF 2,3,5-TRIMETHYLHYDROQUINONE FROM 2,3,6-TRIMETHYLPHENOL | DSM IP ASSETS B.V. (NL) | 2021-06-24 | — | — | WO | disclosed |
| US-20180110225-A1 | HERBICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2018-04-26 | — | — | US | disclosed |
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | HUTCHINSON ALAN J (US) | 2011-11-17 | — | — | US | disclosed |
| US-7863454-B2 | 3-substituted-6-aryl pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-01-04 | — | — | US | disclosed |
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DARPHARMA, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-07-09 | — | — | US | disclosed |
| CN-101170985-A | Hardenable antimicrobial dental compositions and methods | 3M INNOVATIVE PROPERTIES CO (US) | 2008-04-30 | — | — | CN | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| EP-0995743-B1 | Derivatives of dihydro- and tetrahydrochinoline as a medicinal antioxydans | SERVIER LAB (FR) | 2003-04-02 | — | — | EP | disclosed |
| US-6350759-B1 | ANTIOXIDATIVE AGENTS FOR OXIDATION STRESS, ESPECIALLY AT THE CEREBRAL LEVEL; | ADIR ET COMPAGNIE (FR) | 2002-02-26 | — | — | US | disclosed |
| EP-0995743-A1 | Derivatives of dihydro- and tetrahydrochinoline as a medicinal antioxydans | ADIR ET COMPAGNIE (FR) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | C3AR1, C5AR1, C5AR2 | NQO1 1047/4885SCN5A 2181/4885ALDH1A1 1966/4885 |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | C3AR1, C5AR1, C5AR2 | NQO1 1047/4885SCN5A 2181/4885ALDH1A1 1966/4885 |
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DRD2, DRD1, DRD3 | NQO1 3263/4885SCN5A 735/4885ALDH1A1 2059/4885 |
| US-20180110225-A1 | HERBICIDAL COMPOUNDS | DDT, HPD, DDC | NQO1 119/4885SCN5A 2754/4885ALDH1A1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.